VericelVCEL +0.70%81 14-Day RSI is 72.16 as of Jul. 01, 2026. GuruFocus rates VCEL with a GF Score™ of 81/100 and a GF Value™ of $54.29 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,422 Biotechnology companies, Vericel ranks worse than 93.67% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-01), Vericel's 14-Day RSI is 72.16.
The industry rank for Vericel's 14-Day RSI or its related term are showing as below:
VCEL's 14-Day RSI is ranked worse than 93.67% of 1422
companies
in the Biotechnology industry
Industry Median: 48.265
vs VCEL: 72.16
Vericel (NAS:VCEL) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Vericel 14-Day RSI Related Terms
VCEL vs NRIX, MLYS, PHVS: 14-Day RSI Comparison
For the Biotechnology subindustry, Vericel's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Vericel's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (VCEL) has a 14-Day RSI of 72.16 as of Jul. 01, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Vericel and its competitors. According to the industry distribution chart, Vericel ranks #1332 out of 1422 companies in the Biotechnology industry, placing it in the top 93.7%.
Is Vericel's 14-Day RSI too high?
Vericel's current 14-Day RSI is 72.16. The Biotechnology industry median 14-Day RSI is 48.27. Vericel's value of 72.16 is 49.5% above this industry median. Based on the distribution chart, Vericel ranks #1332 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vericel has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's 14-Day RSI compare to NRIX and MLYS?
According to the Biotechnology industry distribution chart, Vericel ranks #1332 out of 1422 companies for 14-Day RSI. This places Vericel in the lower half of its industry. The industry median 14-Day RSI is 48.27. Vericel's value of 72.16 is 49.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.27, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vericel's current 14-Day RSI of 72.16 is 49.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Vericel and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vericel's current 14-Day RSI is 72.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $54.29, compared to a current price of $44.80 — trading 17.5% below its estimated fair value. The current 14-Day RSI is 72.16 and 49.5% above the Biotechnology industry median of 48.27. Vericel's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Vericel (VCEL), the current 14-Day RSI is 72.16 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $44.80 is trading 17.5% below its estimated GF Value™ of $54.29.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
14-Day RSI: 72.16
GF Value™: $54.29 vs. price of $44.80 (17.5% below fair value)
Industry Position: 49.5% above the Biotechnology median (#1332 of 1422)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score
Get the complete analysis for VCEL
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 